Aspirin, lysine, mifepristone and doxycycline combined can effectively and safely prevent and treat cancer metastasis: Prevent seeds from gemmating on soil

Oncotarget

Volumn 6, Issue 34, 2015, Pages 35157-35172

  Wan, Liyuan ^a   Dong, Haiyan ^a   Xu, Huo ^a   Ma, Ji ^a   Zhu, Yewei ^a   Lu, Yusheng ^a   Wang, Jichuang ^a   Zhang, Ting ^a   Li, Tao ^a   Xie, Jingjing ^a   Xu, Bo ^b   Xie, Fangwei ^c   Gao, Yu ^a   Shao, Jingwei ^a   Tu, Xiaohuang ^c   Jia, Lee ^a  

^a FUZHOU UNIVERSITY   (China)

^b FUZHOU GENERAL HOSPITAL   (China)

^c XIAMEN UNIVERSITY   (China)

Author keywords

Cancer metastasis; Cell adhesion molecules; Drug combination; HAMPT; Metastasis chemoprevention

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA4 INTEGRIN; DOXYCYCLINE HYCLATE; INTERCELLULAR ADHESION MOLECULE 1; LYSINE; MIFEPRISTONE; ANTINEOPLASTIC AGENT; DOXYCYCLINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER PREVENTION; CELL ADHESION; CELL VIABILITY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DEATH; DOSE RESPONSE; DOWN REGULATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; EC50; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; LUNG METASTASIS; MALE; MELANOMA CELL LINE; METASTASIS; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PROTEIN EXPRESSION; RAT; THROMBOCYTE ACTIVATION; TUMOR INVASION; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; C57BL MOUSE; DRUG INTERACTION; MELANOMA; MELANOMA, EXPERIMENTAL; PATHOLOGY; RANDOMIZATION; SPRAGUE DAWLEY RAT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPIRIN; DOXYCYCLINE; DRUG INTERACTIONS; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LYSINE; MALE; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MIFEPRISTONE; NEOPLASM METASTASIS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84946865945     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6038     Document Type: Article

References (58)

1. de Moor JS, Mariotto AB, Parry C, Alfano CM, Padgett L, Kent EE, Forsythe L, Scoppa S, Hachey M, Rowland JH. Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomarkers Prev. 2013; 22: 561-570.
2. Goss PE, Chambers AF. Does tumour dormancy offer a therapeutic target?. Nat Rev Cancer. 2010; 10: 871-877.
3. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014; 64: 252-271.
4. Leong SP, Tseng WW. Micrometastatic cancer cells in lymph nodes, bone marrow, and blood: Clinical significance and biologic implications. CA Cancer J Clin. 2014; 64: 195-206.
5. Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, Beitsch PD, Leitch M, Hoover S, Euhus D, Haley B, Morrison L, Fleming TP, et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res. 2004; 10: 8152-8162.
6. Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, Inserra EJ, Ulman M, Springer S, Nakamura Z, Moore AL, Tsukrov DI, Kempner ME, et al. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med. 2010; 2: 25ra23.
7. Rustin GJ, Van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, Kristensen G, Mediola C, Coens C, Qian W, Parmar MK, Swart AM. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010; 376: 1155-1163.
8. Eccles SA, Welch DR. Metastasis: recent discoveries and novel treatment strategies. Lancet. 2007; 369: 1742-1757.
9. Kim M-Y, Oskarsson T, Acharyya S, Nguyen D X, Zhang X H-F, Norton L, Massagué J. Tumor self-seeding by circulating cancer cells. Cell. 2009; 139: 1315-1326.
10. Liang XJ, Meng H, Wang Y, He H, Meng J, Lu J, Wang PC, Zhao Y, Gao X, Sun B, Chen C, Xing G, Shen D, et al. Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis. Proc Natl Acad Sci U S A. 2010; 107: 7449-7454.
11. Daenen LG, Roodhart JM, van Amersfoort M, Dehnad M, Roessingh W, Ulfman LH, Derksen PW, Voest EE. Chemotherapy Enhances Metastasis Formation via VEGFR-1-Expressing Endothelial Cells. Cancer Res. 2011; 71: 6976-6985.
12. Ameri K, Luong R, Zhang H, Powell A, Montgomery K, Espinosa I, Bouley DM, Harris AL, Jeffrey SS. Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype. Br J Cancer. 2010; 102: 561-569.
13. Yu S, Yang X, Zhu Y, Xie F, Lu Y, Yu T, Yan C, Shao J, Gao Y, Mo F, Cai G, Sinko PJ, Jia L. Systems pharmacology of mifepristone (RU486) reveals its 47 hub targets and network: comprehensive analysis and pharmacological focus on FAK-Src-Paxillin complex. Sci Rep. 2015; 5: 7830.
14. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013; 19: 1423-1437.
15. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol. 1994; 124: 619-626.
16. Lu Y, Yu T, Liang H, Wang J, Xie J, Shao J, Gao Y, Yu S, Chen S, Wang L, Jia L. Nitric oxide inhibits heteroadhesion of cancer cells to endothelial cells: restraining circulating tumor cells from initiating metastatic cascade. Sci Rep. 2014; 4: 4344.
17. Wang J, Chen J, Wan L, Shao J, Lu Y, Zhu Y, Ou M, Yu S, Chen H, Jia L. Synthesis, spectral characterization, and in vitro cellular activities of metapristone, a potential cancer metastatic chemopreventive agent derived from mifepristone (RU486). AAPS J. 2014; 16: 289-298.
18. Xie J, Dong H, Chen H, Zhao R, Sinko PJ, Shen W, Wang J, Lu Y, Yang X, Xie F, Jia L. Exploring cancer metastasis prevention strategy: interrupting adhesion of cancer cells to vascular endothelia of potential metastatic tissues by antibody-coated nanomaterial. J Nanobiotechnology. 2015; 13: 9.
19. Jiang Z, Yang J, Pang Y, Yang X, Yu S, Jia L. Bioactivityguided fast screen and identification of cancer metastasis chemopreventive components from raw extracts of Murraya exotica. J Pharm Biomed Anal 2015; 107: 341-345.
20. Humphries MJ, Olden K, Yamada KM. A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. Science. 1986; 233: 467-470.
21. Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011; 11: 123-134.
22. Wang J, Jiang Z, Xiang L, Li Y, Ou M, Yang X, Shao J, Lu Y, Lin L, Chen J, Dai Y, Jia L. Synergism of ursolic acid derivative US597 with 2-deoxy-D-glucose to preferentially induce tumor cell death by dual-targeting of apoptosis and glycolysis. Sci Rep. 2014; 4.
23. Mathijssen RH, Sparreboom A, Verweij J. Determining the optimal dose in the development of anticancer agents. Nat Rev Clin Oncol. 2014; 11: 272-281.
24. Liu X, Jia L. The conduct of drug metabolism studies considered good practice (I): analytical systems and in vivo studies. Curr Drug Metab. 2007; 8: 815.
25. Jia L, Schweikart K, Tomaszewski J, Page J G, Noker P E, Buhrow S A, Reid JM, Ames MM, Munn DH. Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption. Food Chem Toxicol. 2008; 46: 203-211.
26. Jia L, Pei R, Lin M, Yang X. Acute and subacute toxicity and efficacy of S-nitrosylated captopril, an ACE inhibitor possessing nitric oxide activities. Food Chem Toxicol. 2001; 39: 1135-1143.
27. Aguirre-Ghiso J A. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2007; 7: 834-846.
28. Perret G. Pharmacological strategies and micrometastasis: what is known? What must be done? Minerva Med. 2010; 101: 163-178.
29. Chen J, Wang J, Shao J, Gao Y, Xu J, Yu S, Liu Z, Jia L. The unique pharmacological characteristics of mifepristone (RU486): from terminating pregnancy to preventing cancer metastasis. Med Res Rev. 2014; 34: 979-1000.
30. Poole AJ, Li Y, Kim Y, Lin SCJ, Lee WH, Eva YHL. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science. 2006; 314: 1467-1470.
31. Holley AK, Kiningham KK, Spitz DR, Edwards DP, Jenkins JT, Moore MR. Progestin stimulation of manganese superoxide dismutase and invasive properties in T47D human breast cancer cells. J Steroid Biochem Mol Biol. 2009; 117: 23-30.
32. El Etreby MF, Liang Y, Lewis RW. Induction of apoptosis by mifepristone and tamoxifen in human LNCaP prostate cancer cells in culture. Prostate. 2000; 43: 31-42.
33. Yuan H, Upadhyay G, Lu J, Kopelovich L, Glazer RI. The chemopreventive effect of mifepristone on mammary tumorigenesis is associated with an anti-invasive and antiinflammatory gene signature. Cancer Prev Res. 2012; 5: 754-764.
34. Murray MJ, Lessey BA. Embryo implantation and tumor metastasis: common pathways of invasion and angiogenesis. Semin Reprod Endocrinol. 1999; 17: 275-290.
35. De Keizer R, Smit J. Mifepristone treatment in patients with surgically incurable sphenoid-ridge meningioma: a longterm follow-up. Eye. 2004; 18: 954-958.
36. Rothwell PM, Wilson M, Price J F, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012; 379: 1591-1601.
37. Reimers MS, Bastiaannet E, Langley RE, van Eijk R, van Vlierberghe RL, Lemmens VE, van Herk-Sukel MP, van Wezel T, Fodde R, Kuppen PJ, Morreau H, van de Velde CJ, Liefers GJ. Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer. JAMA Intern Med. 2014; 174: 732-739.
38. Bruno A, Dovizio M, Tacconelli S, Patrignani P. Mechanisms of the antitumoural effects of aspirin in the gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2012; 26: e1-e13.
39. Jiang M, Liao C, Lee P. Aspirin inhibits matrix metalloproteinase-2 Activity, increases E-Cadherin production, and inhibits in vitro invasion of tumor cells. Biochem Biophys Res Commun. 2001; 282: 671-677.
40. Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelialmesenchymal-like transition and promotes metastasis. Cancer Cell. 2011; 20: 576-590.
41. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012; 13: 518-527.
42. Gamba CA, Swetter SM, Stefanick ML, Kubo J, Desai M, Spaunhurst KM, et al. Aspirin is associated with lower melanoma risk among postmenopausal Caucasian women. Cancer. 2013; 119: 1562-1569.
43. Barbie DA, Kennedy BK. Doxycycline: new tricks for an old drug. Oncotarget. 2015; 6:19336-19337.
44. Pulvino M, Chen L, Oleksyn D, Li J, Compitello G, Rossi R, Spence S, Balakrishnan V, Jordan C, Poligone B, Casulo C, Burack R, Shapiro JL, et al. Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline. Oncotarget. 2015; 6:14796-14813.
45. Lamb R, Fiorillo M, Chadwick A, Ozsvari B, Reeves KJ, Smith DL, Clarke RB, Howell SJ, Cappello AR, MartinezOutschoorn UE, Peiris-Pagès M, Sotgia F, Lisanti MP. Doxycycline down-regulates DNA-PK and radiosensitizes tumor initiating cells: Implications for more effective radiation therapy. Oncotarget. 2015; 6:14005-14025.
46. Fife RS, Sledge Jr GW. Effects of doxycycline on in vitro growth, migration, and gelatinase activity of breast carcinoma cells. J Lab Clin Med. 1995; 125: 407-411.
47. Fife RS, Sledge Jr GW, Roth BJ, Proctor C. Effects of doxycycline on human prostate cancer cells in vitro. Cancer Lett. 1998; 127: 37-41.
48. Rudek MA, Figg WD, Dyer V, Dahut W, Turner ML, Steinberg SM, Liewehr DJ, Kohler DR, Pluda JM, Reed E. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J Clin Oncol. 2001; 19: 584-592.
49. Silva AS, Yunes JA, Gillies RJ, Gatenby RA. The potential role of systemic buffers in reducing intratumoral extracellular pH and acid-mediated invasion. Cancer Res. 2009; 69: 2677-2684.
50. Rofstad E K, Mathiesen B, Kindem K, Galappathi K. Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. Cancer Res. 2006; 66: 6699-6707.
51. Ibrahim-Hashim A, Wojtkowiak JW, de Lourdes Coelho Ribeiro M, Estrella V, Bailey KM, Cornnell HH, Gatenby RA, Gillies RJ. Free Base Lysine Increases Survival and Reduces Metastasis in Prostate Cancer Model. J Cancer Sci Ther. 2011; Suppl 1.
52. Huang R, Southall N, Wang Y, Yasgar A, Shinn P, Jadhav A, Nguyen DT, Austin CP. The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci Transl Med. 2011; 3: 80ps16.
53. Roomi M W, Ivanov V, Kalinovsky T, Niedzwiecki A, Rath M. In vivo antitumor effect of ascorbic acid, lysine, proline and green tea extract on human prostate cancer PC-3 xenografts in nude mice: evaluation of tumor growth and immunohistochemistry. In Vivo. 2005; 19: 179-183.
54. Pilowsky P M. Aspirin is associated with lower melanoma risk among postmenopausal Caucasian women: the Women's Health Initiative. Cancer. 2013; 119: 3737.
55. Xie J, Zhao R, Gu S, Dong H, Wang J, Lu Y, Sinko PJ, Yu T, Xie F, Wang L, Shao J, Jia L. The architecture and biological function of dual antibody-coated dendrimers: enhanced control of circulating tumor cells and their heteroadhesion to endothelial cells for metastasis prevention. Theranostics. 2014; 4: 1250-1263.
56. Dong H, Yang X, Xie J, Xiang L, Li Y, Ou M, Chi T, Liu Z, Yu S, Gao Y, Chen J, Shao J, Jia L. UP12, a novel ursolic acid derivative with potential for targeting multiple signaling pathways in hepatocellular carcinoma. Biochem Pharmacol. 2015; 93: 151-162.
57. Xie J. Lu Y, Dong H, Zhao R, Chen H, Shen W, Sinko PJ, Zhu Y, Wang J, Shao J, Gao Y, Xie F, Jia L. Enhanced specificity in capturing and restraining circulating tumour cells with dual antibody-dendrimer conjugates. Adv Funct Mater. 2015; 15, 1304-1313.
58. Xie F, Li K, Ouyang X. Twist, an independent prognostic marker for predicting distant metastasis and survival rates of esophageal squamous cell carcinoma patients. Clin Exp Metastasis. 2009; 26: 1025-1032.